Primrose Bio, a San Diego biotechnology company that aims to improve the manufacture of next-generation therapeutics, has begun a partnership to jointly develop and market products for mRNA medicines.
ExploRNA Therapeutics, a biotechnology company in Poland that is advancing mRNA technologies, vaccines and therapeutics, will join with Primrose on the project.
The landscape of mRNA medicines is evolving, marked by an expanding pipeline of drug candidates and advancements in drug design and delivery, leading to pressing challenges in manufacturing.
Primrose Bio’s expertise in engineering high-performance RNA polymerases enhances both the yield and fidelity of mRNA synthesis, effectively reducing double-stranded RNA (dsRNA) and lowering costs.
This advancement meets the rigorous manufacturing demands for a wide range of mRNA-based applications in therapeutics and vaccines.
ExploRNA Therapeutics specializes in innovations of mRNA as a therapeutic platform, focusing on novel cap analogs vital for successful protein production.
Their technology significantly increases that production compared to standard cap analogs, limits dsRNA formation and brings down costs, offering promise in therapeutic effectiveness.
“We are excited to work with ExploRNA to bring industry-leading mRNA cap analogs to the market and pairing them with Primrose Bio’s RNA polymerases,” said Helge Zieler, CEO of Primrose Bio. “This partnership will result in broader manufacturing and design options for companies developing mRNA therapeutics and vaccines, facilitating access to the most efficient capping chemistry available.”
Together, Primrose Bio and ExploRNA will co-develop and offer RNA polymerases and capping compounds, co-optimized to enhance mRNA quality, manufacturing performance and therapeutic safety and efficacy.
“Through joining forces, we’ll advance the mRNA as a modality from the first applications to the next generation,” said Jacek Jemielity, CEO of ExploRNA Therapeutics. “We aim at creating the best synergies between our cap analogs and novel polymerases to surpass current manufacturing process and what is achievable with mRNA today.”
